Adapting a fatigue-management program for adults with sickle cell disease
Adapting the FACETS Fatigue Management Program to Sickle Cell Disease
This trial will test a combined cognitive-behavioral and energy-conservation program (Drépa-FACETS) to reduce fatigue in French-speaking adults with sickle cell disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Versailles Hospital Academic / other |
| Locations | 2 sites (Grenoble and 1 other locations) |
| Trial ID | NCT06650813 on ClinicalTrials.gov |
What this trial studies
The study adapts the FACETS program—an approach that combines cognitive-behavioral techniques with practical energy-conservation strategies—for adults living with sickle cell disease. Participants who speak French will attend program sessions and complete home exercises while researchers collect fatigue and related quality-of-life measures. People with severe psychiatric illness, other chronic causes of fatigue, or who are currently hospitalized for vaso-occlusive crisis are excluded. The intervention is delivered at hospital sites in France and outcomes will compare baseline and post-program fatigue symptoms.
Who should consider this trial
Good fit: Adults with a major sickle cell syndrome who can read and speak French and are not currently hospitalized for a vaso-occlusive crisis are ideal candidates.
Not a fit: Patients with other chronic conditions causing fatigue, severe psychiatric disorders, current vaso-occlusive crises or those who cannot participate in French-language sessions are unlikely to benefit from this program.
Why it matters
Potential benefit: If successful, the program could reduce daily fatigue and improve functioning and quality of life for adults with sickle cell disease.
How similar studies have performed: Similar FACETS-style programs have shown benefit for fatigue in conditions like multiple sclerosis and other chronic illnesses, but adapting this approach specifically for sickle cell disease is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant having freely given his oral agreement. * Participant with a major sickle cell syndrome, regardless of genotype (e.g. SS, SC, Sbeta). * Participant with a sufficient command of spoken and written French to take the assessments, complete the questionnaires, follow the program sessions and carry out the home exercises. Exclusion Criteria: * Participant with one or more severe psychiatric pathologies (e.g. severe depression, psychosis) that could interfere with the conduct of the study, in particular the primary and secondary endpoints. * Participants with another chronic pathology causing fatigue. * Participants in vaso-occlusive crisis (VOC) or hospitalization. * Participant under legal protection (guardianship, curatorship, safeguard of justice, deprived of liberty).
Where this trial is running
Grenoble and 1 other locations
- CHU Grenoble Alpes — Grenoble, France (Recruiting)
- Hospital Versailles — Le Chesnay, France (Completed)
Study contacts
- Study coordinator: Michalina DANNOUNE
- Email: mdannoune@ght78sud.fr
- Phone: 0139638856
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.